The effect of bucolome and amiodarone, inhibitors of CYP2C9, on the pharmacokinetics of losartan

被引：0
|
作者：
Takagi, Miho [1 ]
Kobayashi, Mariko [1 ]
Fukumoto, Kyoko [1 ]
Ueno, Kazuyuki [1 ]
机构：
[1] Niigata Univ, Dept Pharmaceut Sci, Niigata, Japan
来源：
THERAPEUTIC DRUG MONITORING | 2007年 / 29卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号：
1001 ;
摘要：
240
引用
收藏
页码：534 / 535
页数：2
相关论文
共 50 条
  • [31] CYP2C9 polymorphisms and CYP2C9*2 genotyping primers
    Goldstein, JA
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 53 (04) : 409 - 410
  • [32] Effect of CYP2C9*3 allele on the pharmacokinetics of naproxen in Korean subjects
    Jung-Woo Bae
    Ji-Hong Kim
    Chang-Ik Choi
    Mi-Jeong Kim
    Hyung-Ji Kim
    Seong-Ae Byun
    Young-Soon Chang
    Choon-Gon Jang
    Young-Seo Park
    Seok-Yong Lee
    Archives of Pharmacal Research, 2009, 32 : 269 - 273
  • [33] EFFECT OF CYP2C9 GENOTYPE FOR PHARMACOKINETICS OF EFAVIRENZ IN VIVO IN CYNOMOLGUS MONKEYS
    Iwasaki, Kazuhide
    Kitsugi, Yusuke
    Ikeda, Kanami
    Yoshikawa, Takahiro
    Uehara, Shotaro
    Uno, Yasuhiro
    Utoh, Masahiro
    Yamazaki, Hiroshi
    DRUG METABOLISM AND PHARMACOKINETICS, 2017, 32 (01) : S39 - S39
  • [34] Effect of a selective CYP2C9 inhibitor on the pharmacokinetics of nateglinide in healthy subjects
    Helene Sabia
    Gangadhar Sunkara
    Monica Ligueros-Saylan
    Yibin Wang
    Harold Smith
    James McLeod
    Pratapa Prasad
    European Journal of Clinical Pharmacology, 2004, 60 : 407 - 412
  • [35] Effect of a selective CYP2C9 inhibitor on the pharmacokinetics of nateglinide in healthy subjects
    Sabia, H
    Sunkara, G
    Ligueros-Saylan, M
    Wang, YB
    Smith, H
    McLeod, J
    Prasad, P
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 60 (06) : 407 - 412
  • [36] Effect of 36 CYP2C9 variants found in the Chinese population on losartan metabolism in vitro
    Wang, Yu-Han
    Pan, Pei-Pei
    Dai, Da-Peng
    Wang, Shuang-Hu
    Geng, Pei-Wu
    Cai, Jian-Ping
    Hu, Guo-Xin
    XENOBIOTICA, 2014, 44 (03) : 270 - 275
  • [37] Effects of CYP2C9*3 and CYP2C9*13 alleles on the pharmacokinetics of celecoxib and its carboxylic metabolite.
    Park, So-Young
    Lee, Hye-In
    Choi, Chang-Ik
    PHARMACOTHERAPY, 2012, 32 (10): : E235 - E235
  • [38] Consequences of CYP2C9 polymorphisms on flurbiprofen pharmacokinetics.
    Lee, CR
    Pieper, JA
    Frye, RF
    Hinderliter, AL
    Blaisdell, JA
    Goldstein, JA
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (02) : P62 - P62
  • [39] Effects of CYP2C9 genetic polymorphisms on the pharmacokinetics of zafirlukast
    Hyun-Jee Lee
    Young-Hoon Kim
    Se-Hyung Kim
    Choong-Min Lee
    Ae-Yun Yang
    Choon-Gon Jang
    Seok-Yong Lee
    Jung-Woo Bae
    Chang-Ik Choi
    Archives of Pharmacal Research, 2016, 39 : 1013 - 1019
  • [40] EFFECTS OF CYP2C9☆13 ALLELE ON THE PHARMACOKINETICS OF IRBESARTAN
    Park, J., I
    Choi, C., I
    Bae, J. W.
    Jang, C. G.
    Lee, S. Y.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2011, 109 : 64 - 64
12345